We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks Market Edge Highlights: Canopy Growth, Tilray Brands, Constellation Brands, Innovative Industrial Properties and Jazz Pharmaceuticals
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 24, 2023 – Zacks Market Edge is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here: (https://www.zacks.com/stock/news/2188109/pot-stocks-values-or-traps)
Pot Stocks: Values or Traps?
Welcome to Episode #381 of the Zacks Market Edge Podcast.
(1:30) - What Impact Will The SAFE Banking Act Have On The Marijuana Industry?
(12:00) - Could Investors See Any Near Term Growth For Cannabis Stocks?
(17:15) - Breaking Down Tilray’s Current Business and Performance
(25:45) - Investing Into Marijuana Through Real Estate
(35:00) - Is Buying Pharmaceuticals A Safer Play For Cannabis Investing?
(41:50) - Episode Roundup: CGC, TLRY, CTZ, IIPR, JAZZ
Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds, and ETFs and how it impacts your life.
This week, Tracey is joined by Zacks Stock Strategist and the editor of Zacks Marijuana Innovator newsletter, Ben Rains, to discuss the pot stocks. Pot stocks were the hottest thing around 5 years ago but after catching a bid during the pandemic, the stocks have now plunged to multi-year lows.
Are there any deals among the stocks? Or are they traps?
Canopy Growth is a North American cannabis and consumer packaged goods company. Its brands include Doja, 7ACRES, Tweed, and Deep Space. Canopy Growth has a market cap of $476 million.
Shares of Canopy Growth have plunged 75% year-to-date and are down 96% over 5-years. It doesn't have a P/E because it has negative earnings.
With a stock under $1.00, is Canopy Growth a value or a trap?
Constellation Brands is a global beer, wine and spirits company that has had an investment in Canopy Growth for several years. However, Constellation Brands has been reducing that investment.
Shares of Constellation Brands are up 1.4% year-to-date and 22% over the last 5 years. It pays a dividend, yielding 1.5%. Constellation has a forward P/E of 20.
Is Constellation Brands a value or a trap?
4. Innovative Industrial Properties, Inc. (IIPR - Free Report)
Innovative Industrial Properties manages specialized properties leased to experienced, state-licensed operators for their regulated cannabis facilities. It is a REIT which owns 108 properties across 19 states. It has a market cap of $2.2 billion.
Shares of Innovative Industrial Properties are down 21% year-to-date but remain up 44.2% over the last 5 years. After the recent sell-off, shares are cheap. Innovative Industrial Properties trades with a forward P/E of 8.9.
Innovative Industrial Properties pays a big dividend, currently yielding 9%. It had increased that dividend by 6% over the prior 12 months through the end of September. In the third quarter, rent collection was 97% through Sep 30, 2023.
Is Innovative Industrial Properties a value or a trap?
Jazz Pharmaceuticals bought GW Pharmaceuticals in 2021. GW Pharma had a cannabidiol drug called Epidiolex. In the third quarter of 2023, Jazz Pharmaceuticals said Epidiolex is being positioned to achieve blockbuster drug status with multiple launches ongoing and anticipated outside of the US through 2024.
Shares of Jazz Pharmaceuticals are down 25% year-to-date and are down 10.5% over the last 5 years. It trades with a forward P/E of just 6.5. Jazz Pharmaceuticals does not pay a dividend.
Is Jazz Pharmaceuticals a value or a trap?
What Else do you Need to Know About the Pot Stocks?
Tune into this week's podcast to find out.
[In full disclosure, Tracey owns shares of IIPR in her personal portfolio. Ben owns shares of STZ and IIPR in the Marijuana Innovator.]
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks Market Edge Highlights: Canopy Growth, Tilray Brands, Constellation Brands, Innovative Industrial Properties and Jazz Pharmaceuticals
For Immediate Release
Chicago, IL – November 24, 2023 – Zacks Market Edge is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here: (https://www.zacks.com/stock/news/2188109/pot-stocks-values-or-traps)
Pot Stocks: Values or Traps?
Welcome to Episode #381 of the Zacks Market Edge Podcast.
Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds, and ETFs and how it impacts your life.
This week, Tracey is joined by Zacks Stock Strategist and the editor of Zacks Marijuana Innovator newsletter, Ben Rains, to discuss the pot stocks. Pot stocks were the hottest thing around 5 years ago but after catching a bid during the pandemic, the stocks have now plunged to multi-year lows.
Are there any deals among the stocks? Or are they traps?
Pot Stocks: Values or Traps?
1. Canopy Growth Corp. (CGC - Free Report)
Canopy Growth is a North American cannabis and consumer packaged goods company. Its brands include Doja, 7ACRES, Tweed, and Deep Space. Canopy Growth has a market cap of $476 million.
Shares of Canopy Growth have plunged 75% year-to-date and are down 96% over 5-years. It doesn't have a P/E because it has negative earnings.
With a stock under $1.00, is Canopy Growth a value or a trap?
2. Tilray Brands, Inc. (TLRY - Free Report)
Tilray Brands is a cannabis-lifestyle and consumer packaged goods company selling 20 brands in 20 countries. It has a market cap of $1.3 billion.
Shares of Tilray are down 33.5% year-to-date. Over the last 5 years, it has fallen 97%. Tilray also doesn't have a P/E as it has negative earnings.
With a stock price under $2.00, is Tilray a value or a trap?
3. Constellation Brands, Inc. (STZ - Free Report)
Constellation Brands is a global beer, wine and spirits company that has had an investment in Canopy Growth for several years. However, Constellation Brands has been reducing that investment.
Shares of Constellation Brands are up 1.4% year-to-date and 22% over the last 5 years. It pays a dividend, yielding 1.5%. Constellation has a forward P/E of 20.
Is Constellation Brands a value or a trap?
4. Innovative Industrial Properties, Inc. (IIPR - Free Report)
Innovative Industrial Properties manages specialized properties leased to experienced, state-licensed operators for their regulated cannabis facilities. It is a REIT which owns 108 properties across 19 states. It has a market cap of $2.2 billion.
Shares of Innovative Industrial Properties are down 21% year-to-date but remain up 44.2% over the last 5 years. After the recent sell-off, shares are cheap. Innovative Industrial Properties trades with a forward P/E of 8.9.
Innovative Industrial Properties pays a big dividend, currently yielding 9%. It had increased that dividend by 6% over the prior 12 months through the end of September. In the third quarter, rent collection was 97% through Sep 30, 2023.
Is Innovative Industrial Properties a value or a trap?
5. Jazz Pharmaceuticals plc (JAZZ - Free Report)
Jazz Pharmaceuticals bought GW Pharmaceuticals in 2021. GW Pharma had a cannabidiol drug called Epidiolex. In the third quarter of 2023, Jazz Pharmaceuticals said Epidiolex is being positioned to achieve blockbuster drug status with multiple launches ongoing and anticipated outside of the US through 2024.
Shares of Jazz Pharmaceuticals are down 25% year-to-date and are down 10.5% over the last 5 years. It trades with a forward P/E of just 6.5. Jazz Pharmaceuticals does not pay a dividend.
Is Jazz Pharmaceuticals a value or a trap?
What Else do you Need to Know About the Pot Stocks?
Tune into this week's podcast to find out.
[In full disclosure, Tracey owns shares of IIPR in her personal portfolio. Ben owns shares of STZ and IIPR in the Marijuana Innovator.]
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch/
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/performance
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.